Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04166630 · ClinicalTrials.gov registry record · NA

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

A NA study of ICU Acquired Weakness, sponsored by Emory University.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT04166630: Completed NA study of ICU Acquired Weakness, sponsored by Emory University.

NCT04166630 is a NA study of ICU Acquired Weakness that has completed, run by Emory University. The registered enrollment target is 22 participants, below the 2,109-participant average among 4 other ICU Acquired Weakness trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04166630, a NA study of ICU Acquired Weakness, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to develop a non-invasive test to diagnose intensive care unit (ICU) acquired weakness that can be administered to both responsive and non-responsive patients. Study participation will involve the measurement of muscle fatigue during a single 30 minute session. Skeletal muscle will be stimulated with an FDA approved clinical electrical stimulator and accelerations will be passively recorded with an accelerometer.

Primary Outcome

The highest acceleration over a single muscle twitch will be used as the peak acceleration. Peak acceleration will be measured in acceleration in number of times gravity (g). Higher twitch acceleration is a better response.

Conditions Studied

Interventions

  • DEVICE Clinical Electrical Stimulator

Study Locations (1)

Georgia

  • Grady Health System - Atlanta

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-02-02
Est. Completion 2021-06-11
Phase NA
Emory University

1,208 total trials

What the finished NCT04166630 record still lists

NCT04166630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 2,109-participant average among 4 other ICU Acquired Weakness trials with a reported enrollment target (99% lower).

The record links to 1 condition, with ICU Acquired Weakness appearing as the primary indexed condition, and to 1 intervention - of which Clinical Electrical Stimulator is the first listed.

NCT04166630 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT04166630 about?

NCT04166630 is a clinical study titled "Diagnosing Intensive Care Unit (ICU) Acquired Weakness". The goal of this study is to develop a non-invasive test to diagnose intensive care unit (ICU) acquired weakness that can be administered to both responsive and non-responsive patients. Study participation will involve the measurement of muscle fatigue during a single 30 minute session. Skeletal mus...

What is the current status of trial NCT04166630?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2021-02-02. Estimated completion is 2021-06-11.

What conditions does trial NCT04166630 study?

This clinical trial studies the following conditions: ICU Acquired Weakness.

What interventions are being tested in trial NCT04166630?

The interventions under investigation include: Clinical Electrical Stimulator (DEVICE).

Who is sponsoring clinical trial NCT04166630?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04166630 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ICU Acquired Weakness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04166630, the US trial registry maintained by the National Library of Medicine. NCT04166630 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.